ArticleJTO clinical and research reports2024

The Impact of Immunotherapy Use in Stage IIIA (T1-2N2) NSCLC: A Nationwide Analysis.

Lye-Yeng Wong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.